A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Keynote-252 / ECHO-301
  • Sponsors Incyte Corporation; Merck Sharp & Dohme
  • Most Recent Events

    • 06 Apr 2018 According to an Incyte Corporation media release, data from this study will be analyzed and submitted for presentation at an upcoming scientific congress.
    • 06 Apr 2018 According to an Incyte Corporation media release, an external Data Monitoring Committee (eDMC) review of data from this trial determined that he study did not meet the primary endpoint of improving progression free survival and is unlikely to reach statistical significance for the second primary endpoint (overall survival). Based on these results and eDMC recommendation, Incyte Corporation has decided to stop the trial early.
    • 06 Apr 2018 According to an Incyte Corporation media release, status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top